To Pay only for Effective Drugs
The state will purchase only effective drugs. If the treatment is ineffective, the funds paid should come back to the public purse. To put such a plan of action into practice, a pilot project for risk sharing or an agreement on risk sharing has been offered. The pilot project suggests investments from the Federal budget in 2017-2019 to create a new administration. It should ensure introduction of a risk-sharing model in Russia and assess treatment effects.
Pharmaceutical companies are already submitting applications with specification of effects, drug indications and prices. These applications are reviewed by the center of expertise and control of the quality of medical aid of the Ministry of Health. It is suggested that drugs against cancers, hepatitis C, multiple sclerosis and rheumatoid arthritis will be included into the pilot project. Currently the issue concerns 14 candidate drugs, manufactured by international companies, including Bayer, BioMarin, Bristol-Myers Squibb, Novartis, Johnson & Johnson, MSD, Sanofi Genzyme, Takeda and Roche. All the candidate drugs must be approved for marketing in Russia.
The final decision on work with the pilot project drug will be taken by the Ministry of health. The legal framework for reimbursement of the cost of ineffective drugs has not been yet developed, but is being elaborated by the Ministry of Health, Ministry of Economic Development and other involved governmental agencies.